Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Elongin C pseudogene 20 (ELOCP20, also known as TCEB1P20) is classified as a processed pseudogene located in the human genome[4]. Unlike the active elongin C gene (ELOC), which is a regulatory subunit in transcriptional elongation complexes and plays a key role in the regulation of RNA polymerase II activity and ubiquitin-mediated proteolysis via cullin-RING ligases[7], ELOCP20 lacks coding potential and is generally considered non-functional. There is no evidence that it encodes a functional protein or plays a direct role in cellular processes or disease mechanisms. As such, it is not considered a molecular target for drug development or therapeutic intervention[4][5]. If you are seeking structured information for a therapeutic or biologically relevant target, you may be looking for the active **Elongin C** protein (gene: ELOC), not this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Elongin C pseudogene 20 (ELOCP20).